Cancer-targeted MDR-1 siRNA delivery using self-cross-linked glycol chitosan nanoparticles to overcome drug resistance

Ji Young Yhee, Seungyong Song, So Jin Lee, Sung Gurl Park, Ki Suk Kim, Myung Goo Kim, Sejin Son, Heebeom Koo, Ick Chan Kwon, Ji Hoon Jeong, Seo Young Jeong, Sun Hwa Kim, Kwang Meyung Kim

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

P-glycoprotein (Pgp) mediated multi-drug resistance (MDR) is a major cause of failure in chemotherapy. In this study, small interfering RNA (siRNA) for Pgp down-regulation was delivered to tumors to overcome MDR in cancer. To achieve an efficient siRNA delivery in vivo, self-polymerized 5′-end thiol-modified siRNA (poly-siRNA) was incorporated in tumor targeting glycol chitosan nanoparticles. Pgp-targeted poly-siRNA (psi-Pgp) and thiolated glycol chitosan polymers (tGC) formed stable nanoparticles (psi-Pgp-tGC NPs), and the resulting nanoparticles protected siRNA molecules from enzymatic degradation. The psi-Pgp-tGC NPs could release functional siRNA molecules after cellular delivery, and they were able to facilitate siRNA delivery to Adriamycin-resistant breast cancer cells (MCF-7/ADR). After intravenous administration, the psi-Pgp-tGC NPs accumulated in MCF-7/ADR tumors and down-regulated P-gp expression to sensitize cancer cells. Consequently, chemo-siRNA combination therapy significantly inhibited tumor growth without systemic toxicity. These psi-Pgp-tGC NPs showed great potential as a supplementary therapeutic agent for drug-resistant cancer.

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalJournal of Controlled Release
Volume198
DOIs
Publication statusPublished - 2015 Jan 28

Fingerprint

Multiple Drug Resistance
P-Glycoprotein
Drug Resistance
Nanoparticles
Small Interfering RNA
Polymers
Neoplasms
Sulfhydryl Compounds
glycol-chitosan
MCF-7 Cells
Intravenous Administration
Doxorubicin
Down-Regulation
Breast Neoplasms
Drug Therapy
Therapeutics
Growth
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Cancer-targeted MDR-1 siRNA delivery using self-cross-linked glycol chitosan nanoparticles to overcome drug resistance. / Yhee, Ji Young; Song, Seungyong; Lee, So Jin; Park, Sung Gurl; Kim, Ki Suk; Kim, Myung Goo; Son, Sejin; Koo, Heebeom; Kwon, Ick Chan; Jeong, Ji Hoon; Jeong, Seo Young; Kim, Sun Hwa; Kim, Kwang Meyung.

In: Journal of Controlled Release, Vol. 198, 28.01.2015, p. 1-9.

Research output: Contribution to journalArticle

Yhee, JY, Song, S, Lee, SJ, Park, SG, Kim, KS, Kim, MG, Son, S, Koo, H, Kwon, IC, Jeong, JH, Jeong, SY, Kim, SH & Kim, KM 2015, 'Cancer-targeted MDR-1 siRNA delivery using self-cross-linked glycol chitosan nanoparticles to overcome drug resistance', Journal of Controlled Release, vol. 198, pp. 1-9. https://doi.org/10.1016/j.jconrel.2014.11.019
Yhee, Ji Young ; Song, Seungyong ; Lee, So Jin ; Park, Sung Gurl ; Kim, Ki Suk ; Kim, Myung Goo ; Son, Sejin ; Koo, Heebeom ; Kwon, Ick Chan ; Jeong, Ji Hoon ; Jeong, Seo Young ; Kim, Sun Hwa ; Kim, Kwang Meyung. / Cancer-targeted MDR-1 siRNA delivery using self-cross-linked glycol chitosan nanoparticles to overcome drug resistance. In: Journal of Controlled Release. 2015 ; Vol. 198. pp. 1-9.
@article{522224adb6764c078ed228e405919689,
title = "Cancer-targeted MDR-1 siRNA delivery using self-cross-linked glycol chitosan nanoparticles to overcome drug resistance",
abstract = "P-glycoprotein (Pgp) mediated multi-drug resistance (MDR) is a major cause of failure in chemotherapy. In this study, small interfering RNA (siRNA) for Pgp down-regulation was delivered to tumors to overcome MDR in cancer. To achieve an efficient siRNA delivery in vivo, self-polymerized 5′-end thiol-modified siRNA (poly-siRNA) was incorporated in tumor targeting glycol chitosan nanoparticles. Pgp-targeted poly-siRNA (psi-Pgp) and thiolated glycol chitosan polymers (tGC) formed stable nanoparticles (psi-Pgp-tGC NPs), and the resulting nanoparticles protected siRNA molecules from enzymatic degradation. The psi-Pgp-tGC NPs could release functional siRNA molecules after cellular delivery, and they were able to facilitate siRNA delivery to Adriamycin-resistant breast cancer cells (MCF-7/ADR). After intravenous administration, the psi-Pgp-tGC NPs accumulated in MCF-7/ADR tumors and down-regulated P-gp expression to sensitize cancer cells. Consequently, chemo-siRNA combination therapy significantly inhibited tumor growth without systemic toxicity. These psi-Pgp-tGC NPs showed great potential as a supplementary therapeutic agent for drug-resistant cancer.",
keywords = "Glycol chitosan, Multi-drug resistance, Nanoparticles, Polymerized siRNA, siRNA delivery",
author = "Yhee, {Ji Young} and Seungyong Song and Lee, {So Jin} and Park, {Sung Gurl} and Kim, {Ki Suk} and Kim, {Myung Goo} and Sejin Son and Heebeom Koo and Kwon, {Ick Chan} and Jeong, {Ji Hoon} and Jeong, {Seo Young} and Kim, {Sun Hwa} and Kim, {Kwang Meyung}",
year = "2015",
month = "1",
day = "28",
doi = "10.1016/j.jconrel.2014.11.019",
language = "English",
volume = "198",
pages = "1--9",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",

}

TY - JOUR

T1 - Cancer-targeted MDR-1 siRNA delivery using self-cross-linked glycol chitosan nanoparticles to overcome drug resistance

AU - Yhee, Ji Young

AU - Song, Seungyong

AU - Lee, So Jin

AU - Park, Sung Gurl

AU - Kim, Ki Suk

AU - Kim, Myung Goo

AU - Son, Sejin

AU - Koo, Heebeom

AU - Kwon, Ick Chan

AU - Jeong, Ji Hoon

AU - Jeong, Seo Young

AU - Kim, Sun Hwa

AU - Kim, Kwang Meyung

PY - 2015/1/28

Y1 - 2015/1/28

N2 - P-glycoprotein (Pgp) mediated multi-drug resistance (MDR) is a major cause of failure in chemotherapy. In this study, small interfering RNA (siRNA) for Pgp down-regulation was delivered to tumors to overcome MDR in cancer. To achieve an efficient siRNA delivery in vivo, self-polymerized 5′-end thiol-modified siRNA (poly-siRNA) was incorporated in tumor targeting glycol chitosan nanoparticles. Pgp-targeted poly-siRNA (psi-Pgp) and thiolated glycol chitosan polymers (tGC) formed stable nanoparticles (psi-Pgp-tGC NPs), and the resulting nanoparticles protected siRNA molecules from enzymatic degradation. The psi-Pgp-tGC NPs could release functional siRNA molecules after cellular delivery, and they were able to facilitate siRNA delivery to Adriamycin-resistant breast cancer cells (MCF-7/ADR). After intravenous administration, the psi-Pgp-tGC NPs accumulated in MCF-7/ADR tumors and down-regulated P-gp expression to sensitize cancer cells. Consequently, chemo-siRNA combination therapy significantly inhibited tumor growth without systemic toxicity. These psi-Pgp-tGC NPs showed great potential as a supplementary therapeutic agent for drug-resistant cancer.

AB - P-glycoprotein (Pgp) mediated multi-drug resistance (MDR) is a major cause of failure in chemotherapy. In this study, small interfering RNA (siRNA) for Pgp down-regulation was delivered to tumors to overcome MDR in cancer. To achieve an efficient siRNA delivery in vivo, self-polymerized 5′-end thiol-modified siRNA (poly-siRNA) was incorporated in tumor targeting glycol chitosan nanoparticles. Pgp-targeted poly-siRNA (psi-Pgp) and thiolated glycol chitosan polymers (tGC) formed stable nanoparticles (psi-Pgp-tGC NPs), and the resulting nanoparticles protected siRNA molecules from enzymatic degradation. The psi-Pgp-tGC NPs could release functional siRNA molecules after cellular delivery, and they were able to facilitate siRNA delivery to Adriamycin-resistant breast cancer cells (MCF-7/ADR). After intravenous administration, the psi-Pgp-tGC NPs accumulated in MCF-7/ADR tumors and down-regulated P-gp expression to sensitize cancer cells. Consequently, chemo-siRNA combination therapy significantly inhibited tumor growth without systemic toxicity. These psi-Pgp-tGC NPs showed great potential as a supplementary therapeutic agent for drug-resistant cancer.

KW - Glycol chitosan

KW - Multi-drug resistance

KW - Nanoparticles

KW - Polymerized siRNA

KW - siRNA delivery

UR - http://www.scopus.com/inward/record.url?scp=84918586982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918586982&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2014.11.019

DO - 10.1016/j.jconrel.2014.11.019

M3 - Article

C2 - 25481438

AN - SCOPUS:84918586982

VL - 198

SP - 1

EP - 9

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

ER -